Physician profile
Sharon Scherl
NPI 1770515595
$87,267.79
in general payments reported to CMS, 2019-2025
43 companies · $6,737 in 2025
The $6,737 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,137 · 2020: $3,540 · 2021: $9,120 · 2022: $3,498 · 2023: $30K · 2024: $33K · 2025: $6,737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Food and Beverage: $13K · Travel and Lodging: $1,644 · Consulting Fee: $1,290 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,875.00 |
| Food and Beverage | $12,807.69 |
| Travel and Lodging | $1,643.96 |
| Consulting Fee | $1,290.00 |
| Education | $356.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $55,371.21 | 2023-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $9,949.17 | 2020-2021 | |
| Journey Medical Corporation | $3,419.57 | 2020-2025 | Emrosi |
| Abbvie INC. | $1,832.85 | 2019-2025 | Rinvoq |
| Epi Health, LLC | $1,644.61 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $1,603.89 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Incyte Corporation | $1,519.96 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $1,513.07 | 2019-2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $1,166.38 | 2019-2025 | |
| Lilly USA, LLC | $1,129.90 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $933.22 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $858.35 | 2020-2025 | Otezla, Otezla |
| Genzyme Corporation | $737.91 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $729.61 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Galderma Laboratories, L.P. | $663.88 | 2019-2025 | Aklief, Oracea, Epsolay |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Scherl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.